Berenberg raised the price target for Sanofi shares to EUR115.00 on Tuesday. They believe this company is doing well in research and development. Sanofi spent over EUR700 million on research and development this year. They recruited more patients for phase 3 trials, especially in immunology and vaccines. Sanofi is making good progress in research and development, in addition to their successful Dupixent drug. They are also making strategic deals to improve their pipeline. Sanofi is expected to get an 8% return on their research and development investment by 2024. This will help the company grow. The new price target suggests a 10% increase in Sanofi’s stock. Berenberg is optimistic about Sanofi’s future and their efforts to expand and improve research and development.
Other Stories
UK wage growth dips in 3-month period till July